{1} Announces Launch Of VISION For Use With Human Growth Hormone In Japan

EXTON, Pa., Aug. 3 /PRNewswire-FirstCall/ -- Antares Pharma, Inc. (BULLETIN BOARD: ANTR) , announced that its Japanese licensee, JCR Pharmaceuticals Co. Ltd. of Ashiya, Japan, has today launched the Twin- Jector(R) EZ II, a new product that combines Antares Pharma's VISION(R) needle-free injection technology with JCR's human growth hormone.

Roger G. Harrison, Ph.D., Chief Executive Officer of Antares Pharma, said, "We are delighted that JCR, a company well recognized in Japan with a well established growth hormone business, is the first company to introduce needle- free technology into this important market." Dr. Harrison further commented, "The use of our needle-free technology in conjunction with human growth hormone has been an important source of revenue for Antares Pharma since 1997 when the company's European licensee, Ferring B.V., first introduced our needle-free technology to that market. For the year ended December 31, 2003, the majority of our reported product revenues was derived from this sector of our business."

In addition, Dr. Harrison indicated, "The Japanese market for human growth hormone products is the highest value market in the world, and, as with all markets for this hormone, is being increasingly differentiated through innovative formulations and delivery devices. We are optimistic that our licensee, JCR Pharmaceuticals, will be able to build its market position through the use of our well proven needle-free device."

Under the terms of the agreement with JCR, Antares Pharma will receive manufacturing margins on sales of devices as well as royalties on the end sales of human growth hormone used in conjunction with the needle-free technology.

About Antares Pharma

Antares Pharma is an emerging specialty pharmaceutical company leveraging its experience in drug delivery systems to enhance product performance of established and developing drugs. The Company's current technology platforms include transdermal (Advanced Transdermal Delivery ATD(TM)) gels, disposable mini-needle injection systems (Vibex(TM)), reusable needle-free injection systems (VISION(R) and Valeo(TM)), and fast-melt oral (Easy Tec(TM)) tablets. The Company currently has active partnering programs with several pharmaceutical and distribution companies for a number of indications and applications, including diabetes, growth disorders, obesity, female sexual dysfunction and other hormone therapy.

Antares Pharma currently distributes its needle-free injector systems in more than 20 countries and markets the same technology for use with human growth hormone through licensees in most major regions of the world. Licensees also market an ibuprofen gel using Antares Pharma's ATD(TM) technology in several major European countries. In addition, Antares Pharma is undertaking development or is conducting research on several product opportunities that will form the basis of its specialty pharma program. Antares Pharma's corporate headquarters is in Exton, Pennsylvania, with subsidiaries performing research, development, manufacturing and product commercialization activities in Minneapolis, Minnesota and Basel, Switzerland.

Statements included in this press release that are not historical in nature are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. The Company cautions readers that forward-looking statements are subject to certain risks and uncertainties, which could cause actual results to differ materially and which are identified from time to time in the Company's reports filed with the U.S. Securities and Exchange Commission. Antares Pharma claims the protection of the Safe Harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.

For more information, visit Antares Pharma's web site at http://www.antarespharma.com/.

Information included on the Company's website is not incorporated herein by reference or otherwise.

Antares Pharma, Inc.